drugset
drugset / Trial / NCT04185077

Bivalirudin in Late PCI for Oatients With STEMI

NCT04185077 ↗

Phase 4 Unknown 1200 enrolled Second Xiangya Hospital of Central South University
RandomizedParallel-groupOpen-labelTreatment

Summary

Bivalirudin is recomended by guidelines during primary PCI procedure for patients with STEMI. However, there is a large number of STEMI patients who missed the primary PCI. So the investigators aim to study the efficiency and safety of bivalirudin as the anticoagulation therapy during late PCI.

Timeline

Start
2019-11-30
Primary completion
2020-12-31
Completion
2020-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Bivalirudin Peptide 1.75 mg/kg —
Comparator Heparin Other / unclassified 100 iu/kg —

Indications

ST-elevation myocardial infarction